Journal
MOLECULAR & CELLULAR PROTEOMICS
Volume 18, Issue 12, Pages 2388-2400Publisher
ELSEVIER
DOI: 10.1074/mcp.RA119.001702
Keywords
Targeted mass spectrometry; cerebrospinal fluid; biomarker; diagnostic; neurodegenerative diseases; multiple reaction monitoring; Creutzfeldt-Jakob disease; prion
Categories
Funding
- Next Generation Fund at the Broad Institute, BroadIgnite
- National Institutes of Health [F31 AI122592]
- National Science Foundation [GRFP 2015214731]
- Bundesministerium fur Gesundheit through Robert Koch Institute [1369-341]
- National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium [NIH/NCI U24-CA210986, NIH/NCI U01 CA214125]
Ask authors/readers for more resources
Therapies currently in preclinical development for prion disease seek to lower prion protein (PrP) expression in the brain. Trials of such therapies are likely to rely on quantification of PrP in cerebrospinal fluid (CSF) as a pharmacodynamic biomarker and possibly as a trial endpoint. Studies using PrP ELISA kits have shown that CSF PrP is lowered in the symptomatic phase of disease, a potential confounder for reading out the effect of PrP-lowering drugs in symptomatic patients. Because misfolding or proteolytic cleavage could potentially render PrP invisible to ELISA even if its concentration were constant or increasing in disease, we sought to establish an orthogonal method for CSF PrP quantification. We developed a multi-species targeted mass spectrometry method based on multiple reaction monitoring (MRM) of nine PrP tryptic peptides quantified relative to an isotopically labeled recombinant protein standard for human samples, or isotopically labeled synthetic peptides for nonhuman species. Analytical validation experiments showed process replicate coefficients of variation below 15%, good dilution linearity and recovery, and suitable performance for both CSF and brain homogenate and across humans as well as preclinical species of interest. In n = 55 CSF samples from individuals referred to prion surveillance centers with rapidly progressive dementia, all six human PrP peptides, spanning the N- and C-terminal domains of PrP, were uniformly reduced in prion disease cases compared with individuals with nonprion diagnoses. Thus, lowered CSF PrP concentration in prion disease is a genuine result of the disease process and not an artifact of ELISA-based measurement. As a result, dose-finding studies for PrP lowering drugs may need to be conducted in presymptomatic at-risk individuals rather than in symptomatic patients. We provide a targeted mass spectrometry-based method suitable for preclinical quantification of CSF PrP as a tool for drug development. PrP in cerebrospinal fluid is measured by targeted mass spectrometry using peptides across protein domains in humans and preclinical species of interest. Peptides are uniformly reduced in patients with prion disease, suggesting that dose-finding studies of PrP-lowering drugs may be most informative in presymptomatic individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available